Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

19.38USD
24 Mar 2017
Change (% chg)

$0.23 (+1.20%)
Prev Close
$19.15
Open
$19.22
Day's High
$19.48
Day's Low
$19.13
Volume
332,240
Avg. Vol
531,289
52-wk High
$39.73
52-wk Low
$15.15

MYGN.OQ

Chart for MYGN.OQ

About

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is... (more)

Overall

Beta: 0.38
Market Cap(Mil.): $1,319.61
Shares Outstanding(Mil.): 68.09
Dividend: --
Yield (%): --

Financials

  MYGN.OQ Industry Sector
P/E (TTM): 19.48 47.84 29.94
EPS (TTM): 0.99 -- --
ROI: 7.30 6.88 13.01
ROE: 9.71 10.85 14.16

BRIEF-Myriad Genetics launches the endopredict test in U.S for patients with breast cancer

* Myriad Genetics launches the endopredict test in the United States for patients with breast cancer Source text for Eikon: Further company coverage:

Mar 13 2017

BRIEF-D. E. Shaw & CO reports 5 pct passive stake in Myriad Genetics -SEC filing

* D. E. Shaw & CO, L.P. Reports a 5 percent passive stake in Myriad Genetics Inc as of February 22, 2017-sec filing Source text for Eikon: Further company coverage:

Mar 06 2017

BRIEF-Myriad Genetics director Henderson buys 6,000 shares of co's common stock on Feb 22-23

* Myriad Genetics Inc director John Henderson reports purchase of 6,000 shares of co's common stock on Feb 22-23 - SEC filing Source text: (http://bit.ly/2mpiARG) Further company coverage:

Feb 23 2017

BRIEF-D. E. Shaw reports 5 pct passive stake in Myriad Genetics

* D. E. Shaw & Co., L.P. reports 5 pct passive stake in Myriad Genetics Inc as of Feb 9 - SEC filing Source text: (http://bit.ly/2lDFO9O) Further company coverage:

Feb 21 2017

BRIEF-Myriad’s provides data on prostate cancer test

* Myriad’s Prolaris® Test significantly improves the risk classification for one third of men diagnosed with localized prostate cancer Source text for Eikon: Further company coverage:

Feb 17 2017

BRIEF-Camber Capital Management reports 5.53 pct passive stake in Myriad Genetics

* Camber Capital Management LLC reports 5.53 percent passive stake in Myriad Genetics Inc as of November 16 - sec filing Source text : http://bit.ly/2fuddBZ Further company coverage:

Nov 28 2016

BRIEF-Myriad will seek Japanese regulatory approval for Bracanalysis CDX

* Myriad will seek Japanese regulatory approval for Bracanalysis Cdx

Nov 07 2016

BRIEF-Myriad Genetics reports fiscal first-quarter 2017 financial results

* Sees fiscal second-quarter 2017 revenue $188-$190 million; sees Q2 2017 adjusted eps $0.23-$0.25; sees Q2 2017 GAAP EPS $0.06-$0.08

Nov 01 2016

BRIEF-Myriad Genetics's melanoma test effectively diagnosed patients in study

* The myriad mypath melanoma test effectively diagnosed patients in the largest outcomes-based study for a melanoma diagnostic Source text for Eikon: Further company coverage:

Oct 27 2016

BRIEF-Myriad's BRACanalysis CDx test accurately identified patients who may benefit from treatment with Olaparib

* Says its BRACanalysis CDx test accurately identified patients who may benefit from treatment with Olaparib

Oct 26 2016

More From Around the Web

Competitors

Earnings vs. Estimates